- Previous Close
21.50 - Open
20.97 - Bid 21.01 x --
- Ask 23.17 x --
- Day's Range
20.97 - 20.97 - 52 Week Range
18.30 - 35.50 - Volume
2,000 - Avg. Volume
35,434 - Market Cap (intraday)
220.185M - Beta (5Y Monthly) -0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-1.88 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Global Longlife Hospital and Research Limited, a multispecialty hospital, provides medical and allied services in India. It offers medical services, such as oncology, ophthalmology, allergy and immunology, pain management, pulmonology, anaesthesiology, cardiology, dermatology, critical care, diabetes and endocrinology, GI medicine, gynecology, infectious disease, nephrology, and neurology; and surgical services, including CVTS, joint replacement orthopaedics, spine surgery, general surgery, onco surgery, GI surgery, neurosurgery, ENT, plastic surgery, trauma centre, urology, laparoscopic surgery, gynaecology, dental surgery, and vascular surgery. The company also provides radiology services consisting of mammography, CT scan, X-ray, ultrasound, endoscopy, and sonography; pathology services, including microbiology, biochemistry, clinical pathology, cyto pathology, haematology, and serology; and other services comprising dialysis, pharmacy, ambulance, dietary, and physiotherapy services. Global Longlife Hospital and Research Limited was Incorporated in 2012 and is based in Ahmedabad, India.
globalhospital.co.inRecent News: GLHRL.BO
View MorePerformance Overview: GLHRL.BO
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLHRL.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLHRL.BO
View MoreValuation Measures
Market Cap
225.75M
Enterprise Value
348.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.81
Price/Book (mrq)
0.83
Enterprise Value/Revenue
19.80
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-112.07%
Return on Assets (ttm)
-9.32%
Return on Equity (ttm)
-4.28%
Revenue (ttm)
17.66M
Net Income Avi to Common (ttm)
-19.79M
Diluted EPS (ttm)
-1.88
Balance Sheet and Cash Flow
Total Cash (mrq)
17.48M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
249.94M